Mounjaro and weight loss tablets: understanding your options

Why people ask about a Mounjaro tablet, and what's actually available

The question comes up a lot. A question our prescribers hear most weeks is some version of: "Can I get Mounjaro as a pill instead?" It is understandable. Needles make some people anxious, and a once-daily tablet feels more familiar than a weekly injection. The short answer is that tirzepatide does not currently exist in tablet form anywhere in the world with a weight-management licence. In the UK, Mounjaro is supplied as a pre-filled KwikPen delivering a subcutaneous dose once weekly.

What has changed recently is the arrival of oral semaglutide as a genuine alternative. On 11 June 2026 the MHRA approved Wegovy tablets, making the UK the first country in Europe to license an oral GLP-1 medicine for weight loss. This is semaglutide in a once-daily tablet form, co-formulated with an absorption enhancer. It is a real, licensed option. It is also a different medicine from tirzepatide, with a different mechanism and different trial evidence, so treating them as interchangeable would be a mistake.

If your main concern is avoiding injections, exploring what oral weight loss medicines are now available is a sensible starting point before your consultation.

What sets Mounjaro apart from any oral option on the market

Tirzepatide's defining characteristic is that it acts on two receptors simultaneously (GIP and GLP-1) rather than one. Tirzepatide is the only dual-agonist weight-loss medicine licensed in the UK, and that distinction drives the trial results that have attracted so much attention.

In the SURMOUNT-1 trial, adults treated with tirzepatide 15mg lost an average of around 20–21% of body weight over 72 weeks alongside lifestyle changes, as published in the New England Journal of Medicine. The subsequent SURMOUNT-5 head-to-head trial showed tirzepatide produced greater average weight loss than semaglutide 2.4mg weekly. No oral medicine has yet matched those figures in trials. The Wegovy tablet (oral semaglutide at 25mg daily) produced around 13.6% average weight loss over 64 weeks among all participants in its phase-3 trial, rising to approximately 17% among those who adhered fully to treatment, a meaningful result, but different from the injection data.

The practical implication: if you are drawn to a tablet because you are needle-averse, that is a completely valid reason. But if the trial numbers are what drew you to tirzepatide in the first place, the route that delivers those numbers is still the injection. Mounjaro for weight loss is still the injection.

Eligibility: what determines whether either medicine is right for you

Both Mounjaro and Wegovy tablets are licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone does not settle the decision; a prescriber also considers your medical history, current medicines, and any contraindications before recommending anything.

Neither medicine is licensed for anyone under 18. Both are not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. People with a personal or family history of medullary thyroid carcinoma, or certain gastrointestinal conditions, will need a careful prescriber discussion before either is considered appropriate.

The NICE appraisal of tirzepatide (TA1026) covers the clinical criteria in detail for those wanting the full picture. For context on how private eligibility works at nume specifically, the frequently asked questions page covers the process step by step.

Making the injection versus tablet decision with a prescriber

This is the decision the skeleton of this page was always building towards: injection or tablet, and does it matter? The honest answer is that it matters, and the right call depends on factors a prescriber is better placed to weigh than a search result.

Some people do better with a once-weekly injection because the dosing schedule is simple and less easy to forget than a daily tablet. Others find the tablet's lack of needles and refrigeration (oral semaglutide is stored at room temperature, which matters if you travel or have no reliable fridge access) genuinely useful. Some have a medical history that makes one option clinically preferable. The questions around Mounjaro's tablet form mostly resolve to this: there is no tablet form of tirzepatide yet, so the injectable Mounjaro and the new oral Wegovy tablet are different medicines, not the same one in different formats.

For a broader look at how these two medicines compare side by side, the weight management overview covers both. If cost is part of your thinking, the Mounjaro price page sets out what private treatment typically involves. When you are ready to have a real prescriber assess your situation, you can check your eligibility with a free consultation at a time that suits you.